long story short for eagle and naden. Spectrum already has rights to market and distribute the ritux. The future earnings from distribution is basically reflected in the share price. Of course no one knows exact future sales but these Pr's on the agreement are no real news for SPPI. It was unknown who would make the drug, but now it is and the answer is viro. A company that is a manufacturer. It is in simple terms as if a company was awarded a contract. And that contract is royalty payments Viropro will continually receive. So you can see SPPI already new they would make money on the deal and so did its shareholders. Vpro on the other hand was an unknown. Im guessing if the FDA and SPPI are both satisfied with impact and production, the patent will be renewed and so will Vpro's contract. Vpro also has a significantly market cap, and this new source of bank only increases their pps only further. The biggest impact this news would have on SPPI's price would be based on whether or not shareholders believed Viropro was a wise choice to manufacture the drug, and since SPPI did in fact rise slightly, it shows that shareholders trust the decision and ultimately think it was a wise choice. I am no Bio analyst and I am sure there are many more variables but with a masters in business and from some due dilligence this is the simple conclusion.
News 
Market Data 
Discover 
